NCI’s use of Cancer Dialogue for biospecimen network blueprint raises legal, procedural questions.
Plan posted for “public comment” on Dialogue’s Web site; who will respond, Dialogue or NCI? Cost estimate of network significantly reduced.
Also Stillman named director, Cold Spring Harbor, Watson is chancellor.
Pollin Prize honors four pioneers in treatment of childhood leukemia.
December Business & Regulatory Report included in this issue.
The Cancer Letter takes two-week break; next issue Jan. 2.
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- Pour a Scotch, we’re talking clinical trials and prediction markets
- Consumers are increasingly accessing U.S. News rankings of cancer hospitals via AI chatbots
2026 report shows no change in the top-five lineup - FDA grants Replimune’s RP1 an accelerated approval on third submission after 10:3 vote from advisory committee
Amid political outcry, advisors accept weak data and give sponsor a chance to complete phase III trial - The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access









